Royalty Pharma EVP Marshall Urist Sells $238.8K Under Rule 10b5-1 Plan

Overview & Transaction Summary

On September 28, 2026, Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc (RPRX), executed a sale of 4,126 Class A Ordinary Shares at an average price of $57.88, yielding gross proceeds of $238,812.88.

Key Highlights

• Pre-Arranged Trading Plan: The transaction was conducted under a Rule 10b5-1 trading plan adopted on June 26, 2026.
• Direct Ownership Impact: Following this sale, Urist directly holds 4,126 Class A Ordinary Shares, representing a 50% reduction in direct holdings.
• Indirect and Underlying Holdings: The insider continues to hold 19,020 Class A Ordinary Shares indirectly through an IRA. Furthermore, footnote remarks disclose substantial equity exposure via limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares exchangeable into 1,356,528 Class A Ordinary Shares (subject to vesting conditions).

Market & Strategic Context

Given that the sale was executed pursuant to a pre-scheduled Rule 10b5-1 plan and represents a negligible fraction of Urist's total direct and underlying economic stake (>3.8 million share equivalents), this transaction is considered routine diversification and bears Low overall trading significance.